2011, nr. 3 - Academia de Ştiinţe a Moldovei

Ştiinţe Medicalein cardiovascular diseases. Clin Chem Lab Med 2004;42:1085–91.7. Lee DH, Steffen LM, Jacobs DR. Associationbetween serum gamma-glutamyltransferase and dietaryfactors: CARDIA study. Am J Clin Nutr 2004; 79(4):600-5.8. Whitfield JB. Gamma-Glutamyl transferase. CritRev Clin Lab Sci 2001; 38:263–355.9. Karlson BW, Wiklund O, Hallgren P, Sjolin M,Lindqvist J, Herlitz J. Ten-year mortality amongst patientswith a very small or unconfirmed acute myocardialinfarction in relation to clinical history, metabolic screeningand signs of myocardial ischemia. J Intern Med, 2000; 247:449–456.10. Rantala AO, Lilja M, Kauma H, SavolainenMJ, Reunanen A, Kesaniemi YA. Gamma-glutamyltranspeptidase and the metabolic syndrome. J Intern Med,2000; 248: 230–238, 2000.11. Nilssen O, Forde OH, Brenn T. The TromsoStudy. Distribution and population determinants of gammaglutamyltransferase.Am J Epidemiol. 1990;132:318–326.12. Ruttmann E, Brant LJ, Concin H, Diem G, RappK, Ulmer H. Gammaglutamyltransferase as a risk factorfor cardiovascular disease mortality: an epidemiologicalinvestigation in a cohort of 163 944 Austrian adults.Circulation. 2005;112:2130 –2137.13. Marchesini G, Brizi M, Bianchi G, Tomassetti S,Bugianesi E, Lenzi M, McCullough AJ, Natale S, ForlaniG, Melchionda N: Nonalcoholic fatty liver disease: afeature of the metabolic syndrome. Diabetes, 2001; 50:1844 –1850.14. Marchesini G, Forlani G: NASH: from liverdiseases to metabolic disorders and back to clinicalhepatology. Hepatology, 2002; 35:497– 499.15. Malnick SD, Beergabel M, Knobler H: Nonalcoholicfatty liver: a common manifestation of a metabolicdisorder. QJM, 2003; 96: 699 –709.16. Ortega E, Koska J, Salbe AD, Tataranni PA,Bunt JC. Related Articles, Links Serum gamma-glutamyltranspeptidase is a determinant of insulin resistanceindependently of adiposity in Pima Indian children. J ClinEndocrinol Metab. 2006; 91:1419 –1422.17. Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol in Adults: ExecutiveSummary of The Third Report of The National CholesterolEducation Program (NCEP) Expert Panel on Detection,Evaluation, and Treatment of High Blood Cholesterol inAdults (Adult Treatment Panel III). JAMA, 2001; 285:2486 –2497.18. Karp DR, Shimooku K, Lipsky PE. Expressionof gamma-glutamyl transpeptidase protects Ramos B cellsfrom oxidation-induced cell death. J Biol Chem 2001; 276:3798–804.19. Paolicchi A, Emdin M, Ghliozeni E, Ciancia E,Passino C, Popoff G, Pompella A. Human atheroscleroticplaques contain gamma-glutamyl transpeptidase enzymeactivity. Circulation. 2004;109:1440.20. Paolicchi A, Minotti G, Tonarelli P et al.Gammaglutamyltranspeptidase-dependent iron347reduction and LDL oxidation: a potential mechanism inatherosclerosis. J Invest Med 1999; 47: 151–60.21. Dominici S, Valentini M, Maellaro E et al. Redoxmodulation of cell surface protein thiols in U937 lymphomacells: the role of gamma-glutamyl transpeptidase-dependentH2O2 production and S-thiolation. Free Radic Biol Med,1999; 27:623–35.22. Ross R. Mechanism of disease: Atherosclerosis— an inflammatory disease. N Engl J Med 1999; 340:115–26.23. Mitchinson MJ. Toxicity of oxidized LDL towardsmouse peritoneal macrophages in vitro. Atherosclerosis1993; 98:17–24.24. Rajagopalan S, Meng XP, Ramasamy S, HarrisonDG, Galis ZS. Reactive oxygen species produced bymacrophage-derived foam cells regulate the activity ofvascular matrix metalloproteinases in vitro. J Clin Invest1996; 98:2572–9.25. Yusuf S, Hawken S, Ounpuu S, Dans T, AvezumA, Lanas F, McQueen M, Budaj A, Pais P, Varigos J,Lisheng L, for the INTERHEART Study Investigators.Effect of potentially modifiable risk factors associated withmyocardial infarction in 52 countries (the INTERHEARTstudy): casecontrol study. Lancet. 2004; 364:937–952.26. Mason JE, Starke RD, Van Kirk JE. Gamma-Glutamyl Transferase: A Novel Cardiovascular RiskBioMarker. Prev Cardiol. 2010;13:36–41.AbstractGamma-glutamyltransferase is an established liverfunction test and a sensitive marker of hepatic inflammation.Recent studies have focused increasing attention on theusefulness of GGT as a predictor of cardiovascular disease.As a result, identifying higher than expected GGT levelsshould alert the physician to study patients more detailed,with the hopeful outcome of preventing unnecessarycardiac-related events and deaths in future years.RezumatGamma-glutamiltransferaza (GGT) se consideră caun test funcţional hepatic şi marker sensibil al inflamaţieihepatice. Studiile recente au atenţionat privind utilitateaGGT ca fiind factor predicator al patologiei cardiovasculare.Determinarea nivelului ridicat al GGT impune studiereadetailată a pacientului cu scopul prevenirii evenimentelorcardiovasculare şi mortalităţii în anii succesivi.РезюмеГамма-глутамилтрансфераза (ГГТ) является признаннымпечёночным тестом и чувствительныммаркером печеночного воспаления. В последних исследованияхвсе большее внимание было сосредоточенона использовании ГГТ как предиктора сердечнососудистыхзаболеваний. Таким образом, определениеповышенного уровня ГГТ должно побудить врача длядетального исследования пациента с целью предотвращенияразвития сердечно-сосудистых осложнений исмерти в последующие годы.